Stockholm – October 07, 2026 -- SciBase Holding AB has recalculated the terms of its series TO 2 warrants following a rights issue of shares resolved by its board on September 3, 2026, cutting the subscription ratio to 0.01 shares per warrant.
Subscription price drops to SEK 37.47 per share under new warrant terms
Each TO 2 warrant now entitles the holder to subscribe for 0.01 new shares at SEK 37.47 per share, down from the original terms set when the instrument was issued alongside SciBase's April 2024 capital raise. The adjustment follows contractual provisions requiring recalculation of warrant terms whenever the company conducts a subsequent rights issue.
Exercise window set for April 3-17, 2029
Warrant holders will be able to subscribe for shares during a 15-day window from April 3 through April 17, 2029, under the revised terms. Full conditions, including provisions for further adjustments tied to future share issues, remain published on the company's website.
DNB Carnegie Investment Bank continues as Certified Adviser
SciBase, listed on Nasdaq First North Growth Market since June 2, 2015, develops the Nevisense point-of-care diagnostic platform combining AI and electrical impedance spectroscopy technology for dermatological skin lesion assessment. DNB Carnegie Investment Bank AB (publ) remains the company's Certified Adviser. CEO Michael Colérus was named as the company contact for the disclosure, submitted for publication on October 7, 2026.